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Abstract
Background: Diabetic cardiomyopathy (DCM) contributes to cardiac failure in diabetic patients.
It is characterized by excessive lipids accumulation, with increased triacylglycerol (TAG) stores, and
fibrosis in left ventricle (LV). The mechanisms responsible are incompletely known and no specific
treatment is presently defined. We evaluated the possible usefulness of two molecules promoting
lipid oxidation, fenofibrate and metformin, in an experimental model of DCM, the Zucker diabetic
rat (ZDF).
Methods: ZDF and controls (C) rats were studied at 7, 14 and 21 weeks. After an initial study at
7 weeks, ZDF rats received no treatment, metformin or fenofibrate until final studies (at 14 or 21
weeks). C rats received no treatment. Each study comprised measurements of metabolic
parameters (plasma glucose, TAG, insulin levels) and sampling of heart for histology and
measurements of TAG content and relevant mRNA concentration.
Results: ZDF rats were insulin-resistant at 7 weeks, type 2 diabetic at 14 weeks and diabetic with
insulin deficiency at 21 weeks. Their plasma TAG levels were increased. ZDF rats had at 7 weeks
an increased LV TAG content with some fibrosis. LV TAG content increased in untreated ZDF rats
at 14 and 21 weeks and was always higher than in C. Fibrosis increased also moderately in
untreated ZDF rats. Metformin and fenofibrate decreased plasma TAG concentrations. LV TAG
content was decreased by metformin (14 and 21 weeks) and by fenofibrate (14 weeks). Fibrosis
was reduced by fenofibrate only and was increased by metformin. Among the mRNA measured,
fenofibrate increased Acyl-CoA Oxidase mRNA level, metformin decreased Acyl-CoA Synthase
and increased AdipoR1 and pro-inflammatory mRNA levels.
Conclusion: Fenofibrate had favourable actions on DCM. Metformin had beneficial effect on TAG
content but not on fibrosis. PPARα agonists could be useful for the prevention and treatment of
DCM.
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Background
Diabetes mellitus increases the risk of cardiovascular dis-
eases and the incidence of heart failure [1,2]. This heart
failure may result from hypertension and/or from acceler-
ated development of coronary atherosclerosis [3]. Dia-
betic patients can also develop a specific cardiomyopathy
called diabetic cardiomyopathy (DCM) [4,5]. Mecha-
nisms responsible for DCM are still poorly understood
but abnormalities in lipid metabolism with increased
accumulation in left ventricle (LV) of intra-cellular lipids,
demonstrated by the increase in triglycerides (TAG) con-
tent [6,7], play an important role [3,8-13]. These abnor-
malities in lipid metabolism could contribute in
particular to the apoptosis of cardiomyocytes and the
development of fibrosis [3,8,10]. This role of excess lipid
stores (lipotoxicity [14]) is supported by experimental
models. Accumulation of lipids in cardiomyocytes,
through overexpression of long-chain acyl-CoA synthase
(ACS) or lipoprotein-lipase (LPL) [12,15] or inhibition of
fatty acid oxidation [16], induces cardiomyopathy. On the
contrary, augmented efflux of lipids from heart reduces its
TAG content and the development of cardiomyopathy
[17,18]. The mechanisms leading to increased heart lipids
accumulation and TAG stores during diabetes are still
debated. Fatty acid oxidation is increased in diabetic heart
[10,19] but the rise in fatty acid uptake could be still more
important resulting in accumulation of lipids [20]. The
rise in uptake could result from increased availability of
plasma substrates (TAG and non esterified fatty acids
(NEFA)) during diabetes, increased expression of mole-
cules involved in fatty acid uptake [10,21] or an associa-
tion of both.
No treatment of DCM has been defined besides treatment
of diabetes. PPARγ agonists reversed in Zucker diabetic
rats (ZDF) heart lipid accumulation and development of
DCM [8]. However thiazolidinediones expand body flu-
ids volume [22], may have adverse effects on cardiac func-
tion and one should be cautious in their utilization [23].
PPARα agonists could be useful: they lower plasma TAG
concentrations [24] and reduce TAG content in skeletal
muscle [25] and heart [26]. In addition PPARα agonists
can prevent LV diastolic dysfunction in OLETF rats [27].
However cardiac-restricted overexpression of PPARα in
mice induces cardiac lipid accumulation and cardiomyop-
athy [9,28]. Although there may be differences between
the effects of overexpression of a transcription factor in a
given tissue and the effects of whole body activation of
this transcription factor expressed at physiological level,
these observations [9,28] raises serious concern on the use
of PPARα agonists in the presence of DCM. Clarifying this
point is all the more important that PPARα agonists are
frequently used in the treatment of hyperlipidemia in dia-
betic subjects. Therefore, we investigated in an experimen-
tal model of DCM, the ZDF rat [8,29] the effects of
fenofibrate, a PPARα agonist used in the treatment of
hypertriglyceridemia [24], on two main manifestations of
DCM, TAG accumulation and fibrosis in LV. Metformin is
widely used in the treatment of type 2 diabetes. It stimu-
lates fatty acid oxidation through the AMP activated
kinase (AMPK) [30] and can reduce lipids accumulation
in the skeletal muscles of ZDF rats [31]. Therefore met-
formin could also lower intra-cellular lipids content in LV
and opposes the development of DCM. We also investi-
gated its effects on the development of DCM in ZDF rats.
Methods
Protocols
Male ZDF rats (fa/fa) (n = 35) and their control littermates
(controls C, +/+) (n = 15) (Charles River, L'Arbresle,
France) arrived at the age of six weeks and were housed in
an animal facility with controlled temperature (22 ± 1°C)
and a 12 h light/dark cycle (light on at 7:00 AM).
Throughout the study they had free access to water and
food. All rats received the diet (Purina 5008, IPS, London,
UK) (protein 26.8%, carbohydrate 56.4% (91% starch,
9% simples carbohydrates), fat 16.7% of caloric value)
recommended for the development of diabetes in male
ZDF rats. Water and food intake, body weight were
recorded five time/week. A first metabolic investigation
was performed in all rats after one week of acclimation (7
weeks old). Thereafter, five rats of the control and ZDF
groups were sacrificed for blood and tissue sampling. The
remaining control rats were divided in two groups (five
rats each); one was sacrificed at the age of 14 weeks after a
second metabolic investigation, the other had metabolic
investigations at 14 and 21 weeks before sacrifice at 21
weeks. ZDF rats were divided in three groups of 10 rats.
One group received only the Purina 5008 diet (ZDF
group); the other groups received also fenofibrate (100
mg/kg/day, mixed with diet, ZDF+F group) or metformin
(300 mg/kg/day, mixed with diet, ZDF+M group), doses
comparable to those used in previous studies in rats [32].
Fenofibrate or metformin administration started only
once the first metabolic investigation was completed and
was continued until the final sacrifice. Five rats of each
group were sacrificed at 14 weeks after a second metabolic
investigation; the remaining five rats were investigated at
14 and 21 weeks before sacrifice at 21 weeks. Experiments
were conducted according to the French laws and regula-
tion for experiments in animals.
Metabolic investigations
Each investigation comprised blood sampling (tail vein)
in the fed state for measurement of plasma insulin, NEFA
and TAG concentrations and of blood glucose level (One
Touch Ultra, Life Technology, Issy-Les-Moulineaux,
France), In addition, an insulin tolerance test (ITT) was
performed in control and ZDF rats at 7 weeks, during the
first metabolic investigation. Food was removed at 07:00Cardiovascular Diabetology 2009, 8:16 http://www.cardiab.com/content/8/1/16
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AM. Insulin (1 unit/kg) was injected intra-peritoneally at
01:00 PM. Blood glucose was measured before and 15, 30,
45, 60, 90 and 120 min after insulin injection.
Five rats of each group were sacrificed at 7, 14 and 21
weeks. Food was removed the morning at 08:00 AM. Rats
were anesthetized at 02:00 PM (pentobarbital IP 60 mg/
kg). Blood (inferior vena cava) was collected, centrifuged
and plasma stored at -20°C until analysis. Heart was
removed, washed with cold isotonic saline and weighed.
LV was quickly collected and weighted. One part was flash
frozen in liquid nitrogen and stored at -80°C until analy-
sis and one part fixed (4% paraformaldehyde) for histo-
logical analysis.
Analytical procedures
Plasma NEFA and TAG were measured by enzymatic
methods [24] and insulin by ELISA (Cristal Chem, Down-
ers Grove, USA). For measurements of LV TAG concentra-
tions, 100 mg of tissue were homogenized in chloroform/
methanol (1:2, v:v). The chloroform phase was collected,
washed with water and dried under nitrogen. Extracted
lipids were dissolved in propanol for enzymatic determi-
nation of TAG concentration.
LV RNAs were purified (TRIZOL, Invitrogen, Cergy-Ponto-
ise, France) and treated with DNase. Total RNA was
reverse transcripted (Superscript II (Invitrogen) and ran-
dom hexamers). Real time PCR was performed in a MyIQ
thermal cycler (Biorad, Marnes La Coquette, France) using
iQSYBR green Supermix. Samples were run in duplicate
along with dilutions of known amounts of target
sequence for quantification of initial cDNA copies.
Results are expressed as the target over 18S RNA concen-
tration ratio. Primer sequences are given in Additional file
1. Cross sections of the LV fixed with formaldehyde and
embedded with paraffin were stained with Sirius Red. For
each LV sample, collagen density was evaluated in two
non-consecutive sections in the epicardial, middle and
endocardial parts of the ventricle as the Sirius Red positive
area over total area ratios Images were acquired with a
Coolscope microscope (Nikon, Tokyo; Japan) (magnifica-
tion × 20) and analyzed blinded with respect to the
appartenance to the different groups.
Statistics
Results are shown as mean ± sem. Intra-groups compari-
sons of values obtained at 7, 14 and 21 weeks for the var-
ious groups of rats (i.e. control, ZDF, ZDF+M and ZDF+F
groups) were performed by one way ANOVA followed by
the Newman-Keuls procedure to locate the differences.
Between groups comparisons of the values obtained for
each metabolic investigation (at 7, 14 or 21 weeks) were
performed by one way ANOVA followed by the Newman-
Keuls test. P < 0.05 was considered as significant. We used
GraphPad Prism 4.0 software (GraphPad, San Diego, CA,
USA).
Results
Food intake and body weight (Table 1)
ZDF rats ate more than control rats throughout the study
(p < 0.001). Fenofibrate and metformin did not modify
food ingestion. At 7 weeks ZDF rats had a higher body
weight than control rats (p < 0.01). There was no differ-
ence in body weight at 7 weeks between ZDF rats who
received fenofibrate or metformin and those who received
no treatment. Control rats gained weight between 7 and
14 weeks (p < 0.01) and between 14 and 21 weeks (p <
0.01). ZDF rats gained weight between 7 and 14 weeks (p
< 0.01), but less than control rats and there was no further
Table 1: Evolution of food intake and of body weight in control rats and in ZDF rats receiving or not fenofibrate (F) or metformin (M).
Food intake (g/day) Control ZDF ZDF + F ZDF + M
7 weeks 18.5 ± 0.4 27.5 ± 0.7 *** 26.7 ± 0.7*** 26.3 ± 0.6***
14 weeks 26.5 ± 0.9 46.9 ± 2.4*** 43.5 ± 2.4*** 47.1 ± 2.1***
21 weeks 26.6 ± 1.0 46.5 ± 3.0 *** 46.9 ± 3.7*** 43.8 ± 2.2***
Body weight (g)
7 weeks 188 ± 4 231 ± 5*** 253 ± 11*** 228 ± 8**
14 weeks 325 ± 14 345 ± 5 314 ± 5$ 360 ± 13
21 weeks 409 ± 9 361 ± 6** 326 ± 8***$ 398 ± 25
Results are shown are mean and sem. * p < 0.05, ** p < 0.01, *** p < 0.001 vs the corresponding control; $ p < 0.05 vs the corresponding ZDF 
group.Cardiovascular Diabetology 2009, 8:16 http://www.cardiab.com/content/8/1/16
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gain at 21 weeks. Their body weight was comparable to
the one of control rats at 14 weeks and lower at 21 weeks
(p < 0.01). Rats receiving fenofibrate gained less weight
than the ZDF group and at 21 weeks their weight was less
than the one of the control and ZDF groups (p < 0.05).
Metformin had no significant effect on body weight of
ZDF rats.
Insulin and metabolites concentrations (Table 2, Table 3 
and Table 4)
- Glucose and insulin levels (table 2)
ZDF rats had at 7 weeks comparable blood glucose con-
centrations but higher plasma insulin (p < 0.01) than con-
trol rats, indicating the presence of insulin-resistance. This
resistance to insulin was confirmed by the ITT (see addi-
tional file 2). Diabetes developed in all ZDF rats around
the tenth week as shown by the increase in water con-
sumption and urinary output. In all ZDF rats at 14 and 21
weeks, glucose was above 25 mM. Plasma insulin
decreased to values comparable to those of control rats at
14 weeks and below the detection level at 21 weeks. Nei-
ther fenofibrate nor metformin modified these evolu-
tions.
- Plasma lipid concentrations (Table 3 and Table 4)
At 7 weeks control and ZDF rats had comparable NEFA
concentrations whereas TAG were higher in ZDF rats (fed
and post-absorptive states). There were no differences in
these parameters (fed state) between ZDF rats receiving
thereafter fenofibrate, metformin or no treatment. Plasma
lipid concentrations were unchanged at 14 and 21 weeks
in control rats. NEFA concentrations were much higher in
diabetic ZDF rats, both at 14 or 21 weeks and in the fed
and post-absorptive state, than both in corresponding
control rats of 14 or 21 weeks and in ZDF rats before the
appearance of diabetes. Neither fenofibrate nor met-
formin modified plasma NEFA levels in ZDF rats. Plasma
TAG were always higher in ZDF than in control rats at 14
and 21 weeks; Compared to those of ZDF rats at 7 weeks,
these values were higher in the fed state (p < 0.01) but not
in the post-absorptive one. Fenofibrate and metformin
decreased plasma TAG levels in the post-absorptive state,
when most TAG originate from liver TAG synthesis and
secretion, with a more marked effect of metformin partic-
ularly at 14 weeks. On the contrary, in the fed state, when
most TAG originate from the absorption of ingested lip-
ids, metformin had no effect and fenofibrate had only a
moderate TAG lowering effect at 14 weeks. These differ-
ences between effects in the fed and post-absorptive states
suggest that both metformin and fenofibrate acted on
plasma TAG levels more by lowering liver TAG secretion
than by increasing plasma TAG clearance.
Heart and LV weight and TAG content (figure 1)
At 7 weeks ZDF rats had moderate and parallel increases
(p < 0.05 vs controls) in heart (880 ± 22 vs 806 ± 19 mg)
and LV weights (604 ± 7 vs 566 ± 7 mg). These weights
were slightly decreased in ZDF rats at 14 and 21 weeks.
The LV over heart weight ratios were unchanged except for
a moderate increase in ZDF rats at 14 weeks (0.712 ±
0.018 vs 0.629 ± 0.024 in control rats p < 0.05). Neither
fenofibrate not metformin modified these parameters in
ZDF rats.
7-week ZDF rats had already higher LV TAG content than
control rats (p < 0.01). In both groups this content
increased at 14 and 21 weeks (p < 0.01) with values
always higher (p < 0.05 or 0.01) in ZDF rats. Fenofibrate
normalized this TAG content at 14 weeks (p < 0.01 vs
untreated ZDF) but had no effect at 21 weeks. Metformin
effect was more marked with significant decreases (p <
0.01) at 14 and 21 weeks. At 21 weeks, TAG content of LV
Table 2: Evolution of plasma glucose and insulin (fed state) in control rats and in ZDF rats receiving or not fenofibrate (F) or 
metformin (M).
Glucose mM Control ZDF ZDF + F ZDF + M
7 weeks 7.4 ± 0.3 7.3 ± 0.3 7.6 ± 0.2 7.4 ± 0.3
14 weeks 7.0 ± 0.4 30.1 ± 0.9*** 31.5 ± 0.5*** 31.6 ± 0.6***
21 weeks 7.6 ± 0.3 30.2 ± 0.2 *** 33.2 ± 0.2*** 34.2 ± 0.4***
Insulin ng/l
7 weeks 4.7 ± 0.7 16.0 ± 3.0** 12.7 ± 0.8** 12.4 ± 1.1**
14 weeks 6.8 ± 1.1 4.3 ± 1.0 5.1 ± 0.7 6.3 ± 0.7
21 weeks 8.5 ± 0.5 <0.5 ** <0.5 ** <0.5 **
Results are shown are mean and sem. ** p < 0.01, *** p < 0.001 vs the corresponding controlCardiovascular Diabetology 2009, 8:16 http://www.cardiab.com/content/8/1/16
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was even lower in ZDF rats receiving metformin than in
control rats (p < 0.05).
Fibrosis
Histological studies showed that collagen deposition
(both interstitial and perivascular) was increased (p <
0.05) in 7-week ZDF rats compared to 7-week control rats
(figure 2, see additional file 3). Collagen deposition
increased moderately with age in control rats (p < 0.05 at
21 weeks). It increased more in untreated ZDF rats with
values always higher than in controls (p < 0.05). This
fibrosis was reduced in the ZDF group receiving fenofi-
brate with a significant decrease at 21 weeks (p < 0.05).
On the contrary, despite the marked decrease in TAG accu-
mulation, fibrosis was not reduced by metformin and was
even increased at 21 weeks (p < 0.05).
mRNA levels in left ventricle (figures 3 and 4)
a) Fatty acids metabolism (figure 3 and 4)
7-week ZDF rats had moderate increases (p < 0.05) in
mRNA concentrations of Fatty Acid Translocase (FAT),
Fatty Acid Transport Protein (FATP) and Acyl-CoA
synthase1 (ACS1), all molecules involved in fatty acids
uptake or activation. Acetyl-CoA carboxylase2 (ACC2)
mRNA levels were comparable in ZDF and control rats
(data not shown). ACC1 mRNA levels were increased in
ZFD rats (p < 0.01) but mRNA level of Fatty Acid Synthase
(FAS), the other enzyme controlling de novo lipogenesis
was decreased (p < 0.01). Expressions in ZDF rats of dia-
cylglycerol-acyl transferase 1 and 2 (DGAT1 and DGAT2),
involved in TAG synthesis, was unchanged. Long chain-
CoA Acyl dehydrogenase (LCAD) and Acyl-CoA Oxidase
Table 3: Evolution of plasma TAG and NEFA (measured in the post-absorptive state) in control rats and in ZDF rats receiving or not 
fenofibrate (F) or metformin (M).
TAG mM Control ZDF ZDF + F ZDF + M
7 weeks 0.47 ± 0.04 4.12 ± 0.48 ***
14 weeks 0.50 ± 0.07 3.79 ± 0.40 *** 2.97 ± 0.77 **$ 1.48 ± 0.42 *$$
21 weeks 0.54 ± 0.04 5.83 ± 1.01 *** 3.26 ± 0.40 ***$ 2.40 ± 0.50 **$
NEFA μM
7 weeks 595 ± 71 491 ± 28
14 weeks 512 ± 59 1150 ± 95 ** 985 ± 68 ** 1052 ± 59 **
21 weeks 485 ± 63 1495 ± 152 *** 1310 ± 152 *** 1158 ± 125 ***
Results are shown are mean and sem. ** p < 0.01, *** p < 0.001 vs the corresponding control; $ p < 0.05, $$ p < 001 vs the corresponding ZDF 
group. These parameters were measured only in rats sacrificed for tissue sampling (n = 5 for each group), therefore they were measured at 7 
weeks only in a group of 5 control and ZDF rats.
Table 4: Evolution of plasma TAG and NEFA (measured in the fed state) in control rats and in ZDF rats receiving or not fenofibrate 
(F) or metformin (M).
TAG mM Control ZDF ZDF + F ZDF + M
7 weeks 0.89 ± 0.06 2.85 ± 0.39 *** 4.09 ± 0.44 *** 3.32 ± 0.29 ***
14 weeks 1.34 ± 0.08 10.40 ± 1.10 *** 6.50 ± 1.19 ***$ 8.60 ± 1.07 ***
21 weeks 1.50 ± 0.12 9.86 ± 0.63 *** 12.10 ± 1.42 *** 13.20 ± 0.57 ***
NEFA μM
7 weeks 550 ± 62 435 ± 43 541 ± 64 523 ± 89
14 weeks 541 ± 64 1062 ± 103 *** 869 ± 107 *** 1098 ± 123 **
21 weeks 416 ± 27 824 ± 115 ** 1121 ± 145 *** 1211 ± 104 ***
Results are shown are mean and sem** p < 0.01, *** p < 0.001 vs the corresponding control group; $ p < 0.05 vs the corresponding ZDF group.Cardiovascular Diabetology 2009, 8:16 http://www.cardiab.com/content/8/1/16
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(ACO), two enzymes of fatty acid oxidation were
increased (p < 0.05).
mRNA levels of control rats at 14 and 21 weeks were com-
parable to values at 7 weeks despite a trend for lower
VLDLr mRNA. In ZDF rats there was a decrease in ACC1
mRNA concentrations at 14 and 21 weeks (p < 0.01 vs 7
weeks) and a trend for lower values in FAT, VLDLr, ACS1
and LCAD mRNA. There was always a trend for higher FAT
and LCAD mRNA in ZDF than in control rats at 14 and 21
weeks but the only significant difference was the persist-
ence of increased FATP mRNA (p < 0.05).
Fenofibrate induced a trend for an increase in FAT (whose
mRNA levels were higher than in control rats p < 0.05),
FATP, LPL, VLDLr and DGAT1 mRNAs both at 14 and 21
weeks but the only significant effects were increases in
ACS1 and ACO (p < 0.05 vs untreated ZDF) at 14 weeks.
Metformin increased VLDLr (p < 0.01 at 14 and 21
weeks), DGAT1 (p < 0.05 at 14 weeks) and DGAT2 (p <
0.05) expressions but induced a trend for lower FAT and
FATP mRNAs at 21 weeks and it clearly decreased ACS1
mRNA at 14 and 21 weeks (p < 0.01). It induced also a
trend for increased LCAD mRNA, that was higher than in
control rats at 14 and 21 weeks (p < 0.05);
Since adiponectin stimulates lipid utilization [33] includ-
ing in cardiomyocytes [34] and there are data suggesting
that PPARα can modify the expression of its receptors,
AdipoR1 and R2, [35] we measured also the expression of
these receptors in LV (figure 5). AdipoR1 and R2 mRNA
levels were comparable in control and untreated ZDF rats
and were not modified by fenofibrate. However, met-
formin increased the expression of AdipoR1 in ZDF at 14
weeks (p < 0.01 vs untreated ZDF and vs Control) and
induced a trend for higher values at 21 weeks.
b) Fibrosis and inflammation (figures 6)
We observed no difference in procollagen3 mRNA
between ZDF and control rats and no modifications dur-
ing the administration of fenofibrate or metformin (data
not shown). Procollagen1 mRNA level was not higher in
ZDF rats than in control rats and was unchanged in the
fenofibrate treated group but was increased by metformin
administration (p < 0.01 at 14 weeks). The expressions of
VCAM-1, Il-6 and MCP-1 were comparable in control and
untreated ZDF rats and unchanged by fenofibrate but all
increased during the administration of metformin.
Endothelin-1 expression was comparable en control and
ZDF rats and unchanged by fenofibrate or metformin
administration (data not shown).
Discussion
ZDF rats had at 7 weeks of age, in agreement with previous
studies [8], heart abnormalities with increased heart and
LV weights, increased TAG content and already presence
of some fibrosis. TAG content and fibrosis increased fur-
ther in more aged rats (14 and 21 weeks old). TAG stores
increased also in control rats and some fibrosis was also
present in 14 and 21 weeks old control rats, but to a less
extent than in ZDF rats. Our results confirm that heart
abnormalities appear early in this model of DCM; they are
present at the initial stage of insulin-resistance (7 weeks
old rats) and are aggravated when diabetes is present (14
and 21 weeks).
TAG accumulation can result from a shift in the fate of
fatty-acyl-CoA toward esterification with a corresponding
decrease in oxidative rate, or from an imbalance between
cellular fatty acid uptake and oxidation, with a more
important increase in uptake than in oxidation, in the
absence of any absolute decrease in lipid oxidation. Zhou
et al [8] suggested that fatty acid oxidation was decreased
in the heart of ZDF rats. However, this is difficult to recon-
cile with the augmented fatty acid oxidation classically
reported in heart during insulin-resistance and diabetes
[10,19,36]. Our finding of increased ACO and LCAD
mRNA levels in 7 weeks old ZDF rats supports indeed an
enhanced lipid oxidation rate. The increased mRNA con-
centrations for FAT, FATP and ACS1 in 7 weeks old ZDF
rats also support the idea that, in addition to an increased
Concentration of triacylglycerols (TAG) in the left ventricle  (LV) of Control and ZDF rats Figure 1
Concentration of triacylglycerols (TAG) in the left 
ventricle (LV) of Control and ZDF rats. ZDF rats were 
untreated (ZDF) or received fenofibrate (ZDF+F) or met-
formin (ZDF+M) after the first metabolic investigation at the 
age of 7 weeks. These parameters were measured only in 
rats sacrificed for tissue sampling (n = 5 for each group), 
therefore they were measured at 7 weeks only in a group of 
control and ZDF rats.* p < 0.05, ** p < 0.01 vs the corre-
sponding control group; $$ p < 0.01 versus the correspond-
ing untreated ZDF groups. For the sake of clarity, differences 
within the control group and the ZDF group between values 
at 7, 14 and 21 weeks are not indicated; these differences are 
indicated in the results section.
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availability of circulating lipid substrates (at least TAG),
the ability of heart to take up and activate fatty acids is
increased. In addition, fatty acid transporters are relocated
from an intra-cellular pool to the plasma membrane in
heart of Zucker rats and this contributes to an enhanced
fatty acid uptake [21]. Therefore, there is evidence that in
7-weeks ZDF rats, in a situation of insulin-resistance, LV
TAG accumulation is induced by an inappropriate
increase in fatty acid uptake resulting itself from increased
substrate availability and enhanced capacity for uptake.
An additional potential source of fatty acids for TAG syn-
thesis is in situ de novo lipogenesis. Both FAS and ACC1
mRNA were present in heart and ACC1 mRNA concentra-
tions were increased in 7 weeks old ZDF rats. However,
FAS mRNA was decreased in these rats. FAS activity is low
in heart [37] and cardiac ACC1 activity is decreased in
insulin resistant and diabetic heart [36]. Therefore, de novo
lipogenesis is a quantitatively minor pathway in heart and
is not enhanced by insulin-resistance and diabetes. The
respective roles of increased circulating lipid substrates
availability and of heart ability to take up fatty acid could
be different in 14 and 21 weeks old ZDF rats, when overt
diabetes is present, from their role in 7-weeks ZDF rats.
Only FATP mRNA remained increased in ZDF rats once
diabetes was present. Therefore, although it remains pos-
sible that the preferential relocation of fatty acids trans-
porters to plasma membrane described in Zucker rats [21]
was always present, our results suggest that in 14 and 21
weeks old ZDF rats the increased uptake and accumula-
tion of lipids by heart result mainly of the large increases
in plasma NEFA and TAG concentrations.
We investigated the potential usefulness for the preven-
tion or treatment of DCM of fenofibrate and metformin.
Fenofibrate had a mild beneficial action since it reduced
fibrosis and, in 14 weeks old rats only, LV TAG content.
These results are consistent with previous reports showing
that PPARα activation decreased skeletal muscle TAG con-
tent [25] and also heart TAG content of db/db mice [26].
They are also consistent also with studies showing an anti-
fibrotic effect of fenofibrate in several models of hyperten-
sive cardiomyopathy [38-40]. They do not support the
concerns for the use of fibrates in humans raised by the
adverse effects in mice of heart-specific overexpression of
PPARα [9,28,41]. Fenofibrate increased at 14 weeks the
expression of ACO but also of ACS1 and induced a trend
for higher expression of FAT, FATP and LPL suggesting a
parallel stimulation of pathways for fatty acids uptake,
activation and oxidation. These results on gene expression
agree with those obtained in cultured cardiomyocytes
[42,43]. Aasum et al found no effect of in vivo administra-
tion of another PPARα activator on the expression of tar-
get genes of PPARα in heart of db/db mice [44]; however
they measured mRNA levels only after ex vivo experiments
with isolated working heart. In our experiments, it is diffi-
cult to determine whether the balance between uptake
and activation on one hand and oxidation on the other
was modified. It is probable that a main effect of fenofi-
brate was to reduce plasma TAG concentration and thus
an important source of fatty acids uptake by heart. This
would agree with the fact that the plasma TAG lowering
effect of fenofibrate was more marked at 14 weeks, when
LV TAG content was reduced, than at 21 weeks, when it
did not reduce LV TAG stores. Whatever the exact mecha-
nism, our data show no deleterious effects but rather ben-
eficial actions of a PPARα agonist on heart TAG
accumulation in this model of DCM. Fibrosis was also
reduced by fenofibrate. This anti-fibrotic effect of PPARα
activators was also observed in hypertensive cardiomyop-
athy and was ascribed in these models to an anti-inflam-
matory action [38-40]. We found in the present model of
DCM no increased expression of pro-inflammatory mole-
cules genes, or any reduction of these expressions by
fenofibrate. Fibrosis in DCM is considered to result from
the apoptosis of cardiomyocytes induced by the accumu-
lation of cytotoxic lipid molecules [8]. Therefore, the
present anti-fibrotic action of fenofibrate in the present
study is probably related to the reduction in lipid accumu-
lation.
Metformin was more effective than fenofibrate in reduc-
ing LV TAG content. This could result also from the
Histological quantification of fibrosis (expressed as per cent  of total areas) in control and ZDF rats Figure 2
Histological quantification of fibrosis (expressed as 
per cent of total areas) in control and ZDF rats. ZDF 
rats were untreated (ZDF) or received fenofibrate (ZDF+F) 
or metformin (ZDF+M) after the first metabolic investigation 
at the age of 7 weeks. These parameters were measured only 
in rats sacrificed for tissue sampling (n = 5 for each group), 
therefore they were measured at 7 weeks only in a group of 
control and ZDF rats. * p < 0.05 vs the corresponding con-
trol group; € p < 0.05 vs the 7 week value of the group; $ p < 
0.05 vs the corresponding untreated ZDF group.
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mRNA concentrations of of genes controlling fatty acids uptake (FAT, FATP, VLDLr, LPL) and activation (ACS1) in left ventri- cles of control and ZDF rats Figure 3
mRNA concentrations of of genes controlling fatty acids uptake (FAT, FATP, VLDLr, LPL) and activation 
(ACS1) in left ventricles of control and ZDF rats. ZDF rats were untreated (ZDF) or received fenofibrate (ZDF+F) or 
metformin (ZDF+M).* p < 0.05, ** p < 0.01 vs the corresponding control group, $ p < 0.05, $$ p < 0.01 vs the corresponding 
untreated group. For the sake of clarity, differences within the control group and the ZDF group between values at 7, 14 and 
21 weeks are not indicated
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mRNA of genes controlling fatty acids synthesis (ACC1, FAS), esterification into TAG (DGAT1 and 2) and oxidation (ACO,  LCAD) Figure 4
mRNA of genes controlling fatty acids synthesis (ACC1, FAS), esterification into TAG (DGAT1 and 2) and oxi-
dation (ACO, LCAD). ZDF rats were untreated (ZDF) or received fenofibrate (ZDF+F) or metformin (ZDF+M).* p < 0.05 
vs the corresponding control group, $ p < 0.05 vs the corresponding untreated group. For the sake of clarity, differences 
within the control group and the ZDF group between values at 7, 14 and 21 weeks are not indicated
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decrease in plasma TAG levels, at least in the post-absorp-
tive state. However, an unexpected finding is the clear
decrease in ACS1 mRNA observed with metformin. ACS1
is the main ACS expressed in heart. ACS2 is expressed at
much lower level and ACS3, 4 and 5 are expressed at neg-
ligible levels [45-47]. ACS1 expression is regulated in
liver, particularly by nutritional factors [47]. In rodents
heart, ACS1 expression is increased par PPARα agonists
[48], in agreement with the present results, but we know
no previous study showing modifications of ACS expres-
sion by metformin or other activators of AMPk, in heart or
in other tissues. Inhibition of ACS1 expression by met-
formin is difficult to reconcile with the idea that met-
formin, through AMPk activation [30], stimulates fatty
acids oxidation, since decreased fatty acids activation
would reduce the availability of substrates for lipid oxida-
tion. Surprisingly, metformin did not reduce fibrosis
despite the decrease in LV TAG content. Moreover the
expressions of procollagen 1 and of pro-inflammatory
and adhesion molecules were increased. Thus, there is in
this situation a discrepancy between lipids accumulation
on one hand, fibrosis and inflammation on the other.
This is surprising since, although metformin did not
decrease circulating levels of C reactive protein and cell
adhesion molecules in subjects with impaired glucose tol-
erance [49], it reduced the TNFα-induced activation of
NFκB and secretion of VCAM-1 and MCP-1 in vascular
endothelial cells [50]. The mechanisms behind this per-
sistent fibrosis and increased inflammation in heart dur-
ing metformin treatment remain unclear. They could be
related to another unexpected finding, the stimulation by
metformin of heart AdipoR1 expression. This increase in
adiponectin receptor expression could result in enhanced
actions of adiponectin on heart. It could contribute to the
decrease in TAG content since adiponectin stimulates
lipid oxidation [33]. With respect to fibrosis and inflam-
mation, correlative studies in non-alcoholic steatohepati-
tis suggest that adiponectin has anti-fibrotic effects [51]
and adiponectin is considered to have rather an anti-
inflammatory actions. However, several studies suggest
that adiponectin, at least its globular form, activates NFκB
and the expression of proinflammatory and adhesion
molecules genes in macrophages, endothelial cells and
cardiac fibroblasts [52-54]. In addition, it stimulates the
proliferation of cardiac fibroblasts and collagen synthesis
[52]. These actions seem mediated mainly through
AdipoR1, the receptor with the highest affinity for globu-
lar adiponectin [55]. Thus metformin-induced increase in
AdipoR1 expression could have contributed to fibrosis
and to the increase of pro-inflammatory and adhesion
molecules genes expression.
Conclusion
we found, in the model used, that fenofibrate had no
adverse but rather favourable actions on DCM with mild
reduction in TAG accumulation and fibrosis. These results
strongly suggest that PPARα activators should not have
deleterious effects on myocardium in subjects with DCM
and could even be useful in such patients. Metformin had
a clear lowering effect on heart TAG content but did not
reduce fibrosis and stimulated the expression of proin-
flammatory and adhesion molecule genes. Further studies
are needed to clarify these effects of metformin, the mech-
anisms behind them and to determine whether they are
present in humans or not.
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